About 16,223 results

ALLMedicine™ Alopecia Center

Research & Reviews  4,289 results

EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines.
Anti-cancer Drugs; Nowaczyk J, Fret K et. al.

Jan 29th, 2023 - Epidermal growth factor receptor (EGFR) is one of therapeutic targets in oncology for solid tumors originating from epithelial tissue, such as non-small-cell lung carcinoma (NSCLC) and breast cancer. EGFR inhibitors used in cancer treatment may ca...

The burden of alopecia areata: a scoping review focusing on quality of life, mental hea...
Journal of the European Academy of Dermatology and Venere... Muntyanu A, Gabrielli S et. al.

Jan 29th, 2023 - Alopecia areata (AA) is a common inflammatory autoimmune disease of the hair which can have a significant negative impact on the quality of life (QoL), mental health, and productivity. The aim of this scoping review is to elucidate the burden of A...

Genotypic Spectrum and its Correlation with Alopecia and Clinical Response in Hereditar...
Calcified Tissue International; Dodamani MH, Lila AR et. al.

Jan 28th, 2023 - Alopecia in hereditary vitamin D resistant rickets (HVDRR) has some correlation with severe rickets and poor overall response. However, these observations are based on small series. Hence, we aim to assess the genotypic spectrum of HVDRR and its c...

Alopecia areata and risk of common infections: a population-based cohort study.
Clinical and Experimental Dermatology; Messenger AG, Harries M et. al.

Jan 27th, 2023 - It is not known whether alopecia areata (AA) is associated with a greater or reduced risk for infection. We undertook a population-based study exploring associations between AA and common infections. We extracted primary care records from the UK O...

Epidermolysis Bullosa with Pyloric Atresia - GeneReviews® - NCBI Bookshelf

Jan 26th, 2023 - Epidermolysis bullosa with pyloric atresia (EB-PA) is characterized by fragility of the skin and mucous membranes, manifested by blistering with little or no trauma; congenital pyloric atresia; renal and/or ureteral anomalies; and protein-losing e...

see more →

Guidelines  3 results

Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss...
The Journal of Dermatology; Manabe M, Tsuboi R et. al.

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Guidelines for management of androgenetic alopecia based on BASP classification--the As...
Journal of the European Academy of Dermatology and Venere... Lee WS, Lee HJ et. al.

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

British Association of Dermatologists' guidelines for the management of alopecia areata...
The British Journal of Dermatology; Messenger AG, McKillop J et. al.

Apr 25th, 2012 - British Association of Dermatologists' guidelines for the management of alopecia areata 2012.|2012|Messenger AG,McKillop J,Farrant P,McDonagh AJ,Sladden M,|diagnosis,etiology,therapy,methods,therapeutic use,methods,methods,methods,

see more →

Drugs  460 results see all →

Clinicaltrials.gov  460 results

SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC

Jan 25th, 2023 - This is a Phase II trial to determine the efficacy and safety of stereotactic body radiation therapy (SBRT) and in situ oncolytic virus therapy used as a window of opportunity treatment before pembrolizumab in patients with metastatic triple negat...

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Jan 25th, 2023 - Study Description: This is a phase 2 open-label study to evaluate the efficacy and safety of the Janus-associated kinase (JAK) inhibitor, ruxolitinib, in severe APECED-associated alopecia areata (AA). Following an 8-wee observation period to asses...

Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia

Jan 13th, 2023 - Patients will be evaluated through clinical assessment, histology, quality of life assessment, and adverse event monitoring. The data gathered from this study will be used to determine the safety and efficacy of the treatment regimen for this subs...

Clinical Application of Stem Cell Educator Therapy in Alopecia Areata

Jan 12th, 2023 - Alopecia areata (AA) is a common autoimmune disease that results in loss of body hair in varying degrees. The condition is estimated to affect more than 6.8 million people in the United States alone (naaf.org), with a worldwide prevalence of 0.1% ...

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Jan 12th, 2023 - PRIMARY OBJECTIVES: I. To determine, in terms of progression-free survival (PFS), the extent of clinical benefit of the addition of adjuvant radiotherapy (RT) to gross total resection (GTR) for patients with newly diagnosed World Health Organizati...

see more →

News  1,252 results

Epidermal Growth Factor Receptor Inhibitor–Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?
William Lewis, MD, Amy Forrestel, MD et. al.

Dec 30th, 2022 - Epidermal growth factor receptor (EGFR) inhibitors cause numerous cutaneous adverse events (AEs), including papulopustular eruptions, paronychia, acral fissures, xerosis, alopecia, and trichomegaly. 1 Symmetrical drug-related intertriginous and fle.

Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
Ivie Obeime, DO, Jorge Larrondo, MD et. al.

Dec 30th, 2022 - With the introduction of the first US Food and Drug Administration (FDA)–approved medication for alopecia areata (AA)—the Janus kinase (JAK) inhibitor, baricitinib—there is an important focus on this disease in the literature and for practicing de.

Study evaluates features of alopecia areata in Hispanic/Latinx patients
Doug Brunk

Dec 29th, 2022 - Among Hispanic/Latinx patients with alopecia areata, the mean age at diagnosis was 33 years, 24% had concomitant atopy, and 18% had one or more coexisting autoimmune conditions, most commonly rheumatoid arthritis. Those are among key findings from.

5-ARIs Not Linked to Risk of Dementia Over the Long Term

Dec 22nd, 2022 - Men taking 5α-reductase inhibitors (5-ARIs), commonly used for androgenic alopecia and benign prostatic hyperplasia (BPH), should be aware of possible adverse psychological effects, researchers warned. In a register-based cohort study of over 2.2 ...

Hair supplements
Naissan O. Wesley, MD

Dec 19th, 2022 - Recent attention has been given to supplements taken to treat hair loss as the first comprehensive review has been published in JAMA Dermatology in November 2022. Drake and colleagues evaluated the safety and efficacy of nutritional supplements fo.

see more →

Patient Education  25 results see all →